TechCoire to Host Leading Life Science Investors, Innovators and Industry Executives...

* Reuters is not responsible for the content in this press release.

Tue Apr 15, 2008 8:35am EDT

TechCoire to Host Leading Life Science Investors, Innovators and Industry Executives at LifeScienceFest 2008

        TechCoire Announces Call for Entries From Life Science
     Entrepreneurs Seeking Capital to Apply to Present at June 3-4
                Conference at UC Davis' Mondavi Center
FOLSOM, Calif.--(Business Wire)--
More than 250 of the life science industry's top investors,
innovators and executives will be on hand June 3-4 at TechCoire's
LifeScienceFest 2008 in Davis, Calif., at the University of
California, Davis' Mondavi Center. The conference will bring together
life science industry experts from medical devices, diagnostics,
bio-tech, bio-informatics, healthcare information technology and
related disciplines to discuss growth strategies for life science
companies and showcase leading innovations, among other activities.

   Only pre-screened companies will be allowed to present at the
Venture Summit on the first day of the conference, and as such,
companies seeking capital must first apply to be considered to
present. Applications to present must be submitted before May 5. Even
if an entrepreneur does not present, the Venture Summit will provide
an unparalleled opportunity to network with key investors with a
history and track record of life science industry investments. Early
bird registration is now open. Register online at
www.lifesciencefest.com today.

   "TechCoire is hosting this event in the Sacramento region because
of the promising innovations occurring in the life science corridor
reaching from here to the San Francisco Bay Area," said TechCoire
founder Gopan Madathil. "TechCoire brings its unique fundraising
conference expertise to the table through events like this, and we're
thrilled for our region to host this powerful collection of top life
science authorities."

   "LifeScienceFest 2008 will bring together some of the best minds
and investors focused on the life science industry, and the conference
offers a great opportunity to network and build powerful connections.
Entrepreneurs should not miss this event," said John Stuart, Managing
Director of Claremont Creek Ventures that will participate in the
event.

   Sponsored by Morrison Foerster and the UC Davis Health System and
supported by BayBio, TVC and other key partners, the exclusive two-day
venture will feature an opportunity to:

   --  Hear from more than 50 leading life science executives and
        top-tier venture capitalists;

   --  Meet more than 20 innovative startups at the Venture Summit
        (Day 1 of the conference);

   --  Network with more than 250 key deal makers in the life science
        and investment community;

   --  Learn about Exit, Merger and Acquisition and Licensing
        strategies to grow your organization; and

   --  Hear success stories and learn best practices to advance your
        business.

   Partial list of participating venture firms include: Angels Forum,
Aphelion Capital, Asset Management Company, Bay City Capital,
Claremont Creek Ventures, DFJ Frontier, Kaiser Permanente Ventures,
Technology Partners, Mohr Davidow Ventures, Prospect Venture Partners,
Proximal Ventures, Psilos Ventures, Saratoga Ventures, Science Futures
Inc, Band of Angels and Wavepoint Ventures, among others.

   About LifeScienceFest 2008 and TechCoire

   LifeScienceFest 2008 is a part of the Investorfest(R) series of
events produced by TechCoire, the leading organization of technology
entrepreneurs and executives from Northern California. For the past
eight years, TechCoire has developed and hosted leading-edge programs
and events focused on helping early stage entrepreneurs. For more
information about LifeScienceFest, visit
http://www.lifesciencefest.com/. For more information about TechCoire,
visit http://techcoire.com/.

The Francisco Group
Daniel Francisco, 916-812-8814
dan@franciscogrp.com

Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.